Reduced Muscle Loss in Patients With NSCLC Taking Fibrates: Findings From a Retrospective Observational Study
Journal of Cachexia, Sarcopenia and Muscle · 2025
DOI: 10.1002/jcsm.70016 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Rahmi Elahjji und 9 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Fibric Acids, Lung Neoplasms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
The cancer‐anorexia‐cachexia syndrome (CACS) is a common and debilitating wasting disorder characterized by loss of skeletal muscle and worse morbidity and mortality. In pre‐clinical studies, CACS is associated with loss of peroxisome proliferator‐activated receptor alpha (PPAR‐α) dependent ketone production in the liver. Fibrates are PPAR‐α agonists that are commonly used to treat dyslipidemia. Treating mice with fibrates was found to prevent skeletal muscle loss. We examine whether patients with cancer treated with PPAR‐α agonists experience less CACS.
Methods
We performed a retrospective cohort study of patients ( N = 6922) at Memorial Sloan Kettering Cancer Center who were diagnosed with non‐small cell lung cancer (NSCLC) between 2002 and 2017 and were incidentally prescribed fenofibrate or gemfibrozil at the time of diagnosis. These patients were compared to a propensity score‐matched control set who were not taking either drug. The primary outcome included a composite outcome of CACS, which included significant weight loss before or after the time of diagnosis. Secondary outcomes included change in cross‐sectional skeletal muscle area over time as measured in serial CT imaging studies and overall survival. Descriptive statistics, Kaplan–Meier analysis and multivariable logistic regression were performed to compare outcomes between the two groups.
Results
Among patients with NSCLC, 149 were taking fenofibrate or gemfibrozil at the time of diagnosis. A 2:1 propensity score‐matched cohort of 298 patients was created that was well‐matched with regard to baseline characteristics. Regarding the primary composite outcome, there was no significant difference in the prevalence of CACS between those taking fibrates and propensity‐matched controls (49.7 vs. 46.6%). When skeletal muscle mass was measured directly using cross‐sectional imaging, patients on fibrates were found to have lost significantly less muscle area over time (−3.3 vs.−4.2%, p = 0.03). There was no difference in overall survival between groups.
Conclusion
Patients with NSCLC taking fibrates at the time of diagnosis lost less muscle area over time. In a secondary analysis, this change was not associated with a change in overall survival, though this study was likely underpowered for this analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medicine, New York, New York, USA.
- University of Rochester Medical Center, Rochester, New York, USA.
- Kaiser Permanente, Oakland, California, USA.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Marcus D Goncalves
Förderung
- Cancer Research UK
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Elahjji, R., Blow, T., Grover, R., Hurd, M. A., Dunne, R. F., Caan, B. J., Cespedes Feliciano, E. M., Plodkowski, A. J., Flory, J. H., & Goncalves, M. D. (2025). Reduced Muscle Loss in Patients With NSCLC Taking Fibrates: Findings From a Retrospective Observational Study. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70016
Vancouver
Elahjji R, Blow T, Grover R, Hurd MA, Dunne RF, Caan BJ, et al. Reduced Muscle Loss in Patients With NSCLC Taking Fibrates: Findings From a Retrospective Observational Study. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.70016
BibTeX
@article{Elahjji2025,
author = {Elahjji, Rahmi and Blow, Tahj and Grover, Rahul and Hurd, Maurice A and Dunne, Richard F and Caan, Bette J and Cespedes Feliciano, Elizabeth M and Plodkowski, Andrew J and Flory, James H and Goncalves, Marcus D},
title = {Reduced Muscle Loss in Patients With NSCLC Taking Fibrates: Findings From a Retrospective Observational Study},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
doi = {10.1002/jcsm.70016}
}
EUVIMED